Eli Lilly LLY shares are trading higher on Wednesday. The strength is potentially in sympathy with Biogen BIIB which gained following a favorable FDA briefing document for its Alzheimer's drug. Lilly's solanezumab had previously failed Alzheimer's trials.
Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.
Eli Lilly shares were trading up 13.93% at $149.32 on Wednesday. The stock has a 52-week high of $170.75 and a 52-week low of $110.51.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
